IMTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Immatics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.08 |
| 52 Week High | US$13.77 |
| 52 Week Low | US$7.15 |
| Beta | 0.75 |
| 11 Month Change | 4.68% |
| 3 Month Change | -2.34% |
| 1 Year Change | 3.16% |
| 33 Year Change | -8.14% |
| 5 Year Change | 17.85% |
| Change since IPO | 25.83% |
Recent News & Updates
Recent updates
Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans
Jul 12
Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now
May 03We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Sep 26We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Jun 12Immatics launches $110M stock offering
Oct 10Cancer immunotherapy biotech Immatics up 18% on 4x normal volume
Jul 19Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation
Jan 29Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher
Dec 16Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Apr 01What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?
Jan 18Immatics reports Q3 results
Dec 02Immatics (IMTX) Investor Presentation - Slideshow
Nov 13Shareholder Returns
| IMTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.7% | 1.4% | 2.6% |
| 1Y | 3.2% | 23.1% | 30.5% |
Return vs Industry: IMTX underperformed the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: IMTX underperformed the US Market which returned 30.5% over the past year.
Price Volatility
| IMTX volatility | |
|---|---|
| IMTX Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMTX has not had significant price volatility in the past 3 months.
Volatility Over Time: IMTX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 542 | Harpreet Singh | www.immatics.com |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.
Immatics N.V. Fundamentals Summary
| IMTX fundamental statistics | |
|---|---|
| Market cap | US$1.25b |
| Earnings (TTM) | -US$82.29m |
| Revenue (TTM) | US$79.11m |
15.7x
P/S Ratio-15.1x
P/E RatioIs IMTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMTX income statement (TTM) | |
|---|---|
| Revenue | €70.87m |
| Cost of Revenue | €133.04m |
| Gross Profit | -€62.17m |
| Other Expenses | €11.54m |
| Earnings | -€73.71m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | -87.72% |
| Net Profit Margin | -104.01% |
| Debt/Equity Ratio | 0% |
How did IMTX perform over the long term?
See historical performance and comparison